Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00789958 · FLOW

Participant flow

S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct · Source last updated 2018-04-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Adjuvant Chemotherapy: Capecitabine, 1500 mg/m\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle; Gemcitabine hydrochloride, 1000 mg/m\^2, IV, Days 1 \& 8 of each cycle. Chemoradiotherapy: Capecitabine, 1330 mg/m\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT; Radiation (RT): 3-dimensional conformal radiation therapy - 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions; intensity-modulated radiation therapy: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.
    id
    FG000
    title
    Adjuvant Chemotherapy + Chemoradiotherapy
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Progression
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      not protocol specified
    5. reasons
      1. group Id
        FG000
        num Subjects
        26
      type
      Not eligible/not analyzable
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        105
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        79
      type
      Eligible and Analyzable
    3. achievements
      1. group Id
        FG000
        num Subjects
        68
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        37
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Adjuvant Chemotherapy: Capecitabine, 1500 mg/m\^2/day, PO, Every 12 hrs on Days 1-14 of each cycle; Gemcitabine hydrochloride, 1000 mg/m\^2, IV, Days 1 \& 8 of each cycle. Chemoradiotherapy: Capecitabine, 1330 mg/m\^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT; Radiation (RT): 3-dimensional conformal radiation therapy - 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions; intensity-modulated radiation therapy: 4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.
    id
    FG000
    title
    Adjuvant Chemotherapy + Chemoradiotherapy
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        4
      type
      Withdrawal by Subject
    3. reasons
      1. group Id
        FG000
        num Subjects
        3
      type
      Progression
    4. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      not protocol specified
    5. reasons
      1. group Id
        FG000
        num Subjects
        26
      type
      Not eligible/not analyzable
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        105
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        79
      type
      Eligible and Analyzable
    3. achievements
      1. group Id
        FG000
        num Subjects
        68
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        37
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice